**INFINERA CORP** Form 4

February 03, 2016

## FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB 3235-0287 Number:

Expires:

**OMB APPROVAL** 

Check this box if no longer subject to

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

January 31, 2005

0.5

Section 16. Form 4 or Form 5 obligations may continue.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

burden hours per response...

Estimated average

See Instruction 1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * Welch David F			2. Issuer Name <b>and</b> Ticker or Trading Symbol INFINERA CORP [INFN]	5. Relationship of Reporting Person(s) to Issuer  (Check all applicable)		
(Last) (First) (Middle)  C/O INFINERA  CORPORATION, 140 CASPIAN  COURT		(Middle)	3. Date of Earliest Transaction	(Check an applicable)		
		ASPIAN	(Month/Day/Year) 02/01/2016	_X_ Director 10% Owner X Officer (give title Other (specify below) President		
(Street)			4. If Amendment, Date Original	6. Individual or Joint/Group Filing(Check		
SUNNYVALE, CA 94089			Filed(Month/Day/Year)	Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person		

	(City)	(State) (Z	Zip) Table	I - Non-D	erivative Securities	Acquired, Disposed	of, or Beneficia	lly Owned
Se	Title of curity nstr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securities on Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)  (A) or Amount (D) Properties of the Amount (D) Properties on Amount (D) Properties of Amount (D) Prop	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
	ommon					14,132	D	
	ommon					273,709	I	See Footnote (1)
	ommon					140,000	I	See Footnote (2)
	ommon					319,493	I	See Footnote

Common Stock						55.	3,750	I	(3) See Footnote	
Common Stock						2,5	500	I	See Footnote (5)	
Reminder: Re	port on a separ	arate line for each class	s of securities benefic	Persons informat required	s who respond to respond to responding to re	pond ained ond ui	rectly. I to the collect I in this form nless the for alid OMB col	n are not rm	SEC 1474 (9-02)	
			tive Securities Acqui uts, calls, warrants, o							
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Numbe orDerivative Securities Acquired or Dispose (D) (Instr. 3, 4 and 5)	ve s l (A) sed of	6. Date Exerc Expiration D (Month/Day/	Pate	7. Title and Underlying (Instr. 3 and	Securities
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount o Number o Shares
Employee Stock Option (Right to Buy)	\$ 2						<u>(6)</u>	08/08/2016	Common Stock	50,000
Employee Stock Option (Right to Buy)	\$ 2						<u>(6)</u>	08/08/2016	6 Common Stock	137,500
Employee Stock Option (Right to Buy)	\$ 8.19						<u>(6)</u>	11/23/2016	Common Stock	75,000
Employee Stock Option (Right to	\$ 7.61						<u>(6)</u>	06/06/2017	7 Common Stock	29,214

(Right to Buy)

Employee					
Stock Option (Right to Buy)	\$ 7.61	<u>(6)</u>	06/06/2017	Common Stock	101,342
Employee Stock Option (Right to Buy)	\$ 7.61	<u>(6)</u>	02/28/2018	Common Stock	2,817
Employee Stock Option (Right to Buy)	\$ 7.61	<u>(6)</u>	02/28/2018	Common Stock	81,683
Employee Stock Option (Right to Buy)	\$ 7.11	<u>(6)</u>	02/10/2019	Common Stock	100,000
Employee Stock Option (Right to Buy)	\$ 7.45	<u>(6)</u>	08/10/2019	Common Stock	150,000
Employee Stock Option (Right to Buy)	\$ 8.58	<u>(6)</u>	02/10/2021	Common Stock	20,250
Employee Stock Option (Right to Buy)	\$ 8.58	<u>(6)</u>	02/10/2021	Common Stock	60,750
Employee Stock Option (Right to Buy)	\$ 8.58	<u>(6)</u>	02/10/2021	Common Stock	39,465
Employee Stock Option (Right to Buy)	\$ 8.58	<u>(6)</u>	02/10/2021	Common Stock	41,535
	<u>(7)</u>	(8)	(8)		20,000

Restricted Stock Units							Common Stock	
Restricted Stock Units	(7)				<u>(9)</u>	<u>(9)</u>	Common Stock	24,000
Restricted Stock Units	<u>(7)</u>				(10)	(10)	Common Stock	41,846
Restricted Stock Units	<u>(7)</u>				(11)	<u>(11)</u>	Common Stock	28,770
Restricted Stock Units	<u>(7)</u>				(12)	<u>(12)</u>	Common Stock	28,770
Restricted Stock Units	<u>(7)</u>	02/01/2016	A	37,500	(13)	<u>(13)</u>	Common Stock	37,500
Restricted Stock Units	<u>(7)</u>	02/01/2016	A	20,923	(14)	<u>(14)</u>	Common Stock	20,923
Restricted Stock Units	<u>(7)</u>	02/01/2016	A	9,015	(15)	<u>(15)</u>	Common Stock	9,015

# **Reporting Owners**

Reporting Owner Name / Address				
	Director	10% Owner	Officer	Other
Welch David F				
C/O INFINERA CORPORATION	X		President	
140 CASPIAN COURT	Λ		President	
SUNNYVALE, CA 94089				

# **Signatures**

/s/ Michael Post, by Power of Attorney 02/03/2016

\*\*Signature of Reporting Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These shares are held directly by The Welch Family Trust, for which Dr. Welch is a trustee.
- (2) These shares are held directly by The Welch Group, for which Dr. Welch is the general partner.

Reporting Owners 4

- (3) These shares are held directly by LRFA, LLC, for which Dr. Welch is the sole managing member.
- (4) These shares are held directly by SEI Private Trust Company, Trustee of The Welch Family Heritage Trust I u/I dated 9/24/01.
- These shares are held directly by Dr. Welch as a trustee for his children. Dr. Welch disclaims beneficial ownership of the shares held in trust for his children, and this report shall not be deemed an admission that Dr. Welch is the beneficial owner of the shares held in trust for his children for purposes of Section 16 or for any other purpose.
- (6) This option is fully-vested.
- (7) Each restricted stock unit ("RSU") represents a contingent right to receive one share of Infinera Corporation common stock.
- (8) These RSUs vest in three annual installments beginning on February 5, 2014.
- (9) These RSUs vest in four annual installments beginning on August 5, 2014.
- (10) These RSUs vest in three annual installments beginning on May 5, 2015.
- (11) These RSUs vest in three annual installments beginning on May 5, 2016.
- (12) These RSUs vest as to 50% of the shares on May 5, 2017 and 50% of the shares on May 5, 2018.
  - On January 30, 2013, Dr. Welch was granted a performance-based RSU award at target for 75,000 shares of common stock, subject to the achievement of certain performance criteria. One-third of the shares are eligible to vest in each performance period up to a maximum of 150% of target. The performance criteria related to these shares were met at 150% of target for the third performance period, as
- of 130% of target. The performance criteria related to these snares were met at 150% of target for the third performance period, as determined by the administrator per the terms of the original grant, and the common stock issuable with respect to these 37,500 performance-based RSUs will vest on February 5, 2016, subject to Dr. Welch's continuous status as a service provider through such date.
- On February 25, 2014, Dr. Welch was granted a performance-based RSU award at target for 41,847 shares of common stock, subject to the achievement of certain performance criteria. One-third of the shares are eligible to vest in each performance period up to a maximum of 150% of target. The performance criteria related to these shares were met at 150% of target for the second performance period, as determined by the administrator per the terms of the original grant, and the common stock issuable with respect to these 20,923 performance-based RSUs will vest on February 5, 2016, subject to Dr. Welch's continuous status as a service provider through such date.
- On February 24, 2015, Dr. Welch was granted a performance-based RSU award at target for 18,030 shares of common stock, subject to the achievement of certain performance criteria. One-third of the shares are eligible to vest in each performance period up to a maximum of 150% of target. The performance criteria related to these shares were met at 150% of target for the first performance period, as determined by the administrator per the terms of the original grant, and the common stock issuable with respect to these 9,015 performance-based RSUs will vest on February 5, 2016, subject to Dr. Welch's continuous status as a service provider through such

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.